1128. Efficacy and Safety of Nelfinavir in Asymptomatic and Mild COVID-19 Patients: A Multicenter, Randomized Controlled Trial

BACKGROUND: Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibited the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. To evaluate the efficacy and safety of nelfinavir, we conducted a randomized controlled trial. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohno, Shigeru, Miyazaki, Taiga, Hosogaya, Naoki, Morimoto, Shinpei, Yamamoto, Hiroshi, Iwami, Shingo, Miyazaki, Yoshitsugu, Hanaoka, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752835/
http://dx.doi.org/10.1093/ofid/ofac492.967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752835/
http://dx.doi.org/10.1093/ofid/ofac492.967

Ejemplares similares